One-bead-one-inhibitor-one-substrate screening of neuraminidase activity

Laiqiang Ying, Jacquelyn Gervay-Hague

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Given the eminent threat of a 21st century flu pandemic, the search for novel antiviral compounds is an increasingly important area of research. Recent developments in antiviral research have established the viability of targeting viral neuraminidase (NA), an enzyme that cleaves sialic acid from the cell-surface-mediating passage of the virus in the respiratory tract. N-acetyl neuraminic acid (NeuAc) is the substrate for NA, and analogues of this core structure have been commercialized as antiviral therapeutics. Recent studies have established that this system is well suited for combinatorial approaches to drug discovery. An important step in the process is to develop solid-phase screening technologies. The feasibility of performing competitive solid-phase NA assays is reported herein. Initially, a fluorogenic NeuAc substrate was immobilized on solid support, and the ability of three NAs (Clostridium perfringens, Salmonella typhimurium, and Vibrio cholerae) to cleave the substrate was shown to be analogous to solution-phase assays. The solid support was then bifunctionalized with the fluorogenic NeuAc substrate and one of two known inhibitors (DANA and Zanamivir). The ability of NA to cleave NeuAc from the solid support when simultaneously presented with an inhibitor was shown to be enzyme dependent. As expected, simultaneous presentation of NeuAc and DANA, a nonspecific inhibitor, led to diminished activity for all three enzymes tested. In contrast, dual presentation of NeuAc and the selective inhibitor Zanamivir only showed significant activity against Vibrio cholerae.

Original languageEnglish (US)
Pages (from-to)1857-1865
Number of pages9
JournalChemBioChem
Volume6
Issue number10
DOIs
StatePublished - Oct 2005

Fingerprint

Neuraminic Acids
Neuraminidase
Screening
Substrates
Zanamivir
Antiviral Agents
Vibrio cholerae
Assays
Enzymes
Clostridium
Clostridium perfringens
Salmonella
N-Acetylneuraminic Acid
Pandemics
Drug Discovery
Salmonella typhimurium
Viruses
Research
Respiratory System
Technology

Keywords

  • Antiviral agents
  • Fluorogenic substrates
  • Inhibitors
  • Neuraminidase
  • Solid-phase reactions

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

One-bead-one-inhibitor-one-substrate screening of neuraminidase activity. / Ying, Laiqiang; Gervay-Hague, Jacquelyn.

In: ChemBioChem, Vol. 6, No. 10, 10.2005, p. 1857-1865.

Research output: Contribution to journalArticle

@article{35f5687e517a43648f1c3952b9ebf441,
title = "One-bead-one-inhibitor-one-substrate screening of neuraminidase activity",
abstract = "Given the eminent threat of a 21st century flu pandemic, the search for novel antiviral compounds is an increasingly important area of research. Recent developments in antiviral research have established the viability of targeting viral neuraminidase (NA), an enzyme that cleaves sialic acid from the cell-surface-mediating passage of the virus in the respiratory tract. N-acetyl neuraminic acid (NeuAc) is the substrate for NA, and analogues of this core structure have been commercialized as antiviral therapeutics. Recent studies have established that this system is well suited for combinatorial approaches to drug discovery. An important step in the process is to develop solid-phase screening technologies. The feasibility of performing competitive solid-phase NA assays is reported herein. Initially, a fluorogenic NeuAc substrate was immobilized on solid support, and the ability of three NAs (Clostridium perfringens, Salmonella typhimurium, and Vibrio cholerae) to cleave the substrate was shown to be analogous to solution-phase assays. The solid support was then bifunctionalized with the fluorogenic NeuAc substrate and one of two known inhibitors (DANA and Zanamivir). The ability of NA to cleave NeuAc from the solid support when simultaneously presented with an inhibitor was shown to be enzyme dependent. As expected, simultaneous presentation of NeuAc and DANA, a nonspecific inhibitor, led to diminished activity for all three enzymes tested. In contrast, dual presentation of NeuAc and the selective inhibitor Zanamivir only showed significant activity against Vibrio cholerae.",
keywords = "Antiviral agents, Fluorogenic substrates, Inhibitors, Neuraminidase, Solid-phase reactions",
author = "Laiqiang Ying and Jacquelyn Gervay-Hague",
year = "2005",
month = "10",
doi = "10.1002/cbic.200500006",
language = "English (US)",
volume = "6",
pages = "1857--1865",
journal = "ChemBioChem",
issn = "1439-4227",
publisher = "Wiley-VCH Verlag",
number = "10",

}

TY - JOUR

T1 - One-bead-one-inhibitor-one-substrate screening of neuraminidase activity

AU - Ying, Laiqiang

AU - Gervay-Hague, Jacquelyn

PY - 2005/10

Y1 - 2005/10

N2 - Given the eminent threat of a 21st century flu pandemic, the search for novel antiviral compounds is an increasingly important area of research. Recent developments in antiviral research have established the viability of targeting viral neuraminidase (NA), an enzyme that cleaves sialic acid from the cell-surface-mediating passage of the virus in the respiratory tract. N-acetyl neuraminic acid (NeuAc) is the substrate for NA, and analogues of this core structure have been commercialized as antiviral therapeutics. Recent studies have established that this system is well suited for combinatorial approaches to drug discovery. An important step in the process is to develop solid-phase screening technologies. The feasibility of performing competitive solid-phase NA assays is reported herein. Initially, a fluorogenic NeuAc substrate was immobilized on solid support, and the ability of three NAs (Clostridium perfringens, Salmonella typhimurium, and Vibrio cholerae) to cleave the substrate was shown to be analogous to solution-phase assays. The solid support was then bifunctionalized with the fluorogenic NeuAc substrate and one of two known inhibitors (DANA and Zanamivir). The ability of NA to cleave NeuAc from the solid support when simultaneously presented with an inhibitor was shown to be enzyme dependent. As expected, simultaneous presentation of NeuAc and DANA, a nonspecific inhibitor, led to diminished activity for all three enzymes tested. In contrast, dual presentation of NeuAc and the selective inhibitor Zanamivir only showed significant activity against Vibrio cholerae.

AB - Given the eminent threat of a 21st century flu pandemic, the search for novel antiviral compounds is an increasingly important area of research. Recent developments in antiviral research have established the viability of targeting viral neuraminidase (NA), an enzyme that cleaves sialic acid from the cell-surface-mediating passage of the virus in the respiratory tract. N-acetyl neuraminic acid (NeuAc) is the substrate for NA, and analogues of this core structure have been commercialized as antiviral therapeutics. Recent studies have established that this system is well suited for combinatorial approaches to drug discovery. An important step in the process is to develop solid-phase screening technologies. The feasibility of performing competitive solid-phase NA assays is reported herein. Initially, a fluorogenic NeuAc substrate was immobilized on solid support, and the ability of three NAs (Clostridium perfringens, Salmonella typhimurium, and Vibrio cholerae) to cleave the substrate was shown to be analogous to solution-phase assays. The solid support was then bifunctionalized with the fluorogenic NeuAc substrate and one of two known inhibitors (DANA and Zanamivir). The ability of NA to cleave NeuAc from the solid support when simultaneously presented with an inhibitor was shown to be enzyme dependent. As expected, simultaneous presentation of NeuAc and DANA, a nonspecific inhibitor, led to diminished activity for all three enzymes tested. In contrast, dual presentation of NeuAc and the selective inhibitor Zanamivir only showed significant activity against Vibrio cholerae.

KW - Antiviral agents

KW - Fluorogenic substrates

KW - Inhibitors

KW - Neuraminidase

KW - Solid-phase reactions

UR - http://www.scopus.com/inward/record.url?scp=26944484395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26944484395&partnerID=8YFLogxK

U2 - 10.1002/cbic.200500006

DO - 10.1002/cbic.200500006

M3 - Article

C2 - 16149103

AN - SCOPUS:26944484395

VL - 6

SP - 1857

EP - 1865

JO - ChemBioChem

JF - ChemBioChem

SN - 1439-4227

IS - 10

ER -